Clinical trial
Anti-CD7 Universal CAR-T Cells for CD7+ T/NK Cell Hematologic Malignancies: a Multi-center, Uncontrolled Trial
NCT04264078 is registered in ClinicalTrials.gov with Xinqiao Hospital of Chongqing as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Anti-CD7 Universal CAR-T Cells for CD7+ T/NK Cell Hematologic Malignancies: a Multi-center, Uncontrolled Trial
- Lead sponsor
- Xinqiao Hospital of Chongqing
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- March 1, 2021
- Completion date
- June 1, 2023
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
t-cell leukemia, t-cell lymphoma